P2–379: Disconnect between brain and CSF drug exposure and beta‐amyloid levels following BACE inhibition
Cathleen Gonzales, David Riddell(Eli Lilly (United States)), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Claude Ambroise(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), Cheng Chang(Pfizer (United States)), Éva Hajós‐Korcsok(Pfizer (United States)), Brian T. O’Neill(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302